

TB NURSE NETWORK MEETING

Wednesday, January 18, 2017

10:00-12:00 PM

Conference call in number: 1-888-557-8511

Passcode: 2544873

Please Remember to Mute Your Phones

Do Not Put Us on Hold

Agenda

Announcements (15 min)

- Upcoming Events & Webinars
- Recently Archived Webinars & Trainings
- TB in the News

Presentation

Overview and Discussion of the 2016 ATS/CDC/IDSA Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis

Peter Davidson, PhD

TB Program Manager, MDHHS

Open Forum

Close and Adjourn

Please Remember to Mute Your Phones
Do Not Put Us on Hold

Upcoming Events

MDHHS 2017 World TB Day

- Monday, March 20th, 2017
- Kellogg Hotel and Conference Center, East Lansing, Michigan
- Registration will be open soon (email announcement); \$50 registration fee
- Nursing & Physician continuing education credits will be available (about 6 hours)
- Tentative Agenda:
 - ❖ Panel: Patient Stories
 - ❖ Epidemiology of TB
 - ❖ TB & Diabetes: A Local Health Department's Approach
 - ❖ Lab Overview & Case Study
 - ❖ New USPSTF LTBI Testing Recommendations
 - ❖ National Tuberculosis Controllers Association (NTCA) Update
 - ❖ New TB Treatment Guidelines for Drug-Susceptible TB
 - ❖ Panel: TB Services for Refugees in Michigan

Upcoming Webinars

Curry International TB Center

[“Exploding Head Zone – The Interface of Molecular and Growth-Base Drug Susceptibility Testing”](#)

- 1/25/17 @ 2-3:30 ET
- Registration ends 1/19/17
- This 75-minute webinar will discuss how to put together results from both conventional growth-based and molecular methods of TB drug susceptibility testing (including conflicting or contradictory results) to request further testing and/or design optimal treatment regimens for TB patients

RTMCCs (Jointly sponsored)

[“Practical Implementation of the 2016 ATS/CDC/IDSA Treatment of Drug-Susceptible Tuberculosis Guidelines: Caveats and Controversies”](#)

- 2/3/17 @ 2-3:30 ET
- Registration ends 1/27/17
- Part 2 of 2 webinar series

Recently Archived Webinars

Mayo Clinic Center for Tuberculosis

- [“Case Studies in Pediatric TB and HIV Co-Infection”](#)

Curry International Tuberculosis Center

- [“2016 ATS/CDC/IDSA Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis Webinar”](#)
- Part 1 of 2 webinar series

Rutgers Global TB Institute

- [“Tricks of the Trade: Strategies for Pediatric TB Case Management”](#)

Recently Archived Trainings: Curry International TB Center

Fundamentals of Tuberculosis Case Management

- This session took place during the TB Case Management and Contact Investigation Intensive which took place in Oakland, CA. It was originally presented on November 1, 2016. A PDF handout of the PowerPoint slides is located [here](#).

Nontuberculosis Mycobacterial Infections

- This session took place during the TB Clinical Intensive which took place in Oakland, CA. It was originally presented on October 2, 2015. A PDF handout of the PowerPoint slides is located [here](#).

TB in the News



[New TB Vaccine Shows Promise in Mice](#) (1/13/17)

- Jason W. Lee et al. **Engineering mycobacteria for the production of self-assembling biopolyesters displaying mycobacterial antigens for use as tuberculosis vaccine.** *Applied and Environmental Microbiology*, January 2017 DOI: [10.1128/AEM.02289-16](https://doi.org/10.1128/AEM.02289-16)
- Polyhydroxyalkanoate (PHA) biobeads with mycobacterial antigens induced significant cell mediated immune responses in mice.
- Biobeads are more natural, biodegradable, inexpensive, and safer compared to other TB vaccines
- [Do we really need a new vaccine against TB?](#) YouTube Video
 - Stefan Kaufmann, director of Max Planck Institute for Infection Biology, in Berlin, and past president of IUIS explains the advantage on the new vaccine for TB his group is testing in clinical trials in Europe and Africa.

[New Protein Identified that is Central to Immune Response Against M. Tb](#) (1/12/17)

- Luis H. Franco, Vidhya R. Nair, Caitlyn R. Scharn, Ramnik J. Xavier, Jose R. Torrealba, Michael U. Shiloh, Beth Levine. **The Ubiquitin Ligase Smurf1 Functions in Selective Autophagy of Mycobacterium tuberculosis and Anti-tuberculous Host Defense.** *Cell Host & Microbe*, 2017; 21 (1): 59 DOI: [10.1016/j.chom.2016.11.002](https://doi.org/10.1016/j.chom.2016.11.002)
- Could be used to develop immune-based therapies to treat TB, eliminating the need for antibiotics and the worry of MDR TB.

Overview and Discussion of the 2016 ATS/CDC/IDSA Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis

Peter Davidson, PhD

TB Program Manager, MDHHS

[American Thoracic Society \(ATS\)/Centers for Disease Control and Prevention \(CDC\)/Infectious Diseases Society of America \(IDSA\) Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis](#)

[CDC's Highlights from the 2016 Treatment of Drug-Susceptible Tuberculosis Guidelines](#)

Open Forum

New TB Treatment Guidelines:

1. Who has read and used the new TB treatment guidelines?
2. What issues/problems have you experienced or foresee in using these new guidelines in your TB control program?
3. What do you like/dislike about the new guidelines?
4. What questions do you have about the new guidelines?

If you would like to continue this conversation, remember to register and join the [“Practical Implementation of the 2016 ATS/CDC/IDSA Treatment of Drug-Susceptible Tuberculosis Guidelines: Caveats and Controversies”](#) webinar on 2/3/17 @ 2-3:30 ET

Other:

Thank you!

Meeting notes and presentations will be sent to everyone on the TB Nurse Network list and posted on our website:

www.michigan.gov/TB

Next TBNN meeting

Wednesday April 19th, 2017

10-12 PM EST

Please contact Helen McGuirk with questions, comments, or suggestions for presentations and content:

mcguirkh@michigan.gov

517-284-4957